Chris Takimoto

Chris Takimoto

Direktör/Styrelseledamot på ALX ONCOLOGY HOLDINGS INC.

Förmögenhet: - $ per 2026-07-31

67 år
Health Technology
Consumer Services

Profil

Chris H.
Takimoto
is currently an Independent Director at ALX Oncology Holdings, Inc. since 2025 and Global Chief Medical Officer at The Start Center For Cancer Research.
Former roles include Chief Medical Officer at IGM Biosciences, Inc. from 2021 to 2024, Senior Vice President-Oncology at Gilead Sciences, Inc. from 2020 to 2021, Chief Medical Officer at Forty Seven LLC from 2016 to 2020, VP-Experimental Medicine Early Development at Janssen Global Services LLC from 2010 to 2016, Senior Director-Translational Medicine at Ortho Biotech Oncology Research & Development from 2008 to 2010, and Associate Professor at the University of Texas Health Science Center At San Antonio.
Education includes undergraduate studies at Stanford University and doctorate degrees from Yale University and Yale School of Medicine.

Kända innehav i offentliga företag

FöretagDatumAntal aktierVärderingVärderingsdatum
2026-03-31 0 ( -.--% ) - $ 2026-07-31

Aktiva positioner av Chris Takimoto

FöretagPositionStart
ALX ONCOLOGY HOLDINGS INC. Direktör/Styrelseledamot 2025-01-21

Tidigare kända positioner av Chris Takimoto

FöretagPositionSlut
IGM BIOSCIENCES, INC. Teknisk/Vetenskaplig/F&U Direktör 2024-10-01
GILEAD SCIENCES, INC. Företagsledare/Principal 2021-07-01
FORTY SEVEN, INC. Teknisk/Vetenskaplig/F&U Direktör 2020-04-01
Företagsledare/Principal 2016-01-01
Ortho Biotech Oncology Research & Development
Företagsledare/Principal 2010-01-01
Se detaljerna i Chris Takimotos erfarenhet

Chris Takimotos utbildningar

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Relationer

65

Första gradens relationer

10

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Kopplade företag

Privata företag10

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Consumer Services

Health Technology

Ortho Biotech Oncology Research & Development

Consumer Services

Health Technology

  1. Börsen
  2. Insiders
  3. Chris Takimoto